News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

Janssen presented SVR12 results from the phase III PROMISE study of simeprevir in treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

Published
22 May 2013
From
Janssen press release
Hepatitis C treatment
Recent Advances in the Treatment of Chronic Hepatitis C Threaten to Leave Some Parts of the World Behind

A scenario may develop where hepatitis C is largely eradicated from the developing world but exits in large pockets in developing countries.

Published
21 May 2013
From
Medscape (requires registration)
New and experimental hepatitis C treatment
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C

The U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.

Published
13 May 2013
From
Janssen press release
New and experimental hepatitis C treatment
New HCV combinations could have a big role in prevention, but only if treatment rates increase

New combinations of hepatitis C drugs could have major public health benefits, a modelling study published in the online edition of Hepatology shows. Scaling-up treatment rates in

Published
11 May 2013
By
Michael Carter
New and experimental hepatitis C treatment
Gilead Reports Interim Data From Phase 2 LONESTAR Study

Company Plans to Initiate Phase 3 Study Evaluating Eight and 12 Weeks of Therapy with Sofosbuvir and Ledipasvir for the Treatment of Chronic Hepatitis C.

Published
03 May 2013
From
Gilead press release
New and experimental hepatitis C treatment
Daclatasvir + asunaprevir + BMS-791352 looks promising as interferon-free combination

An all-oral regimen containing three next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1

Published
02 May 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets

A new analysis from Frost & Sullivan, "Analysis of European Hepatitis B and C Therapeutics Markets" finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period.

Published
01 May 2013
From
PR Newswire
New and experimental hepatitis C treatment
Compassionate access to new hepatitis C drugs an "emergency" for European patients

European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis,

Published
30 April 2013
By
Keith Alcorn
New and experimental hepatitis C treatment
Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C

A second-generation hepatitis C protease inhibitor, faldaprevir, cured up to 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated

Published
30 April 2013
By
Keith Alcorn
New and experimental hepatitis C treatment
Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80%

A second-generation hepatitis C protease inhibitor, simeprevir, cured around 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon

Published
30 April 2013
By
Keith Alcorn
← First12345...32Next →

Filter by country